Plasma Levels of Soluble HLA-E and HLA-F at Diagnosis May Predict Overall Survival of Neuroblastoma Patients

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2013 Dec 19

PMID 24350297

Citations 18

Authors

Fabio Morandi

Giuliana Cangemi

Sebastiano Barco

Loredana Amoroso

Maria Giuliano

Anna Rita Gigliotti

Vito Pistoia

Maria Valeria Corrias

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to identify the plasma/serum biomarkers that are able to predict overall survival (OS) of neuroblastoma (NB) patients. Concentration of soluble (s) biomarkers was evaluated in plasma (sHLA-E, sHLA-F, chromogranin, and B7H3) or serum (calprotectin) samples from NB patients or healthy children. The levels of biomarkers that were significantly higher in NB patients were then analyzed considering localized or metastatic subsets. Finally, biomarkers that were significantly different in these two subsets were correlated with patient's outcome. With the exception of B7H3, levels of all molecules were significantly higher in NB patients than those in controls. However, only chromogranin, sHLA-E, and sHLA-F levels were different between patients with metastatic and localized tumors. sHLA-E and -F levels correlated with each other but not chromogranin. Chromogranin levels correlated with different event-free survival (EFS), whereas sHLA-E and -F levels also correlated with different OS. Association with OS was also detected considering only patients with metastatic disease. In conclusion, low levels of sHLA-E and -F significantly associated with worse EFS/OS in the whole cohort of NB patients and in patients with metastatic NB. Thus, these molecules deserve to be tested in prospective studies to evaluate their predictive power for high-risk NB patients.

Citing Articles

HLA-E and Its Soluble Form as Indicators of a Sex-Specific Immune Response in Patients with Oral Squamous Cell Carcinoma.

Radermacher A, Fehrenz M, Bellin T, Classen C, Moller L, Struckmeier A Int J Mol Sci. 2023; 24(23).

PMID: 38069020 PMC: 10706335. DOI: 10.3390/ijms242316699.

Significance of HLA-E and its two NKG2 receptors in development of complications after allogeneic transplantation of hematopoietic stem cells.

Siemaszko J, Lacina P, Szymczak D, Szeremet A, Majcherek M, Czyz A Front Immunol. 2023; 14:1227897.

PMID: 37901227 PMC: 10611459. DOI: 10.3389/fimmu.2023.1227897.

Non-Classical HLA Determinants of the Clinical Response after Autologous Stem Cell Transplantation for Systemic Sclerosis.

Boukouaci W, Lansiaux P, Lambert N, Picard C, Clave E, Cras A Int J Mol Sci. 2022; 23(13).

PMID: 35806227 PMC: 9266677. DOI: 10.3390/ijms23137223.

HLA-E circulating and genetic determinants in schizophrenia and bipolar disorder.

Boukouaci W, Lajnef M, Richard J, Wu C, Bouassida J, Rafik I Sci Rep. 2021; 11(1):20260.

PMID: 34642395 PMC: 8511156. DOI: 10.1038/s41598-021-99732-9.

Lesion human leukocyte antigen-E is associated with favourable prognosis for patients with oesophageal squamous cell carcinoma.

Xu Y, Du X, Li Z, Fang Z, Zhang F J Int Med Res. 2021; 49(10):3000605211047278.

PMID: 34617814 PMC: 8504691. DOI: 10.1177/03000605211047278.

References

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

De Bernardi B, Mosseri V, Rubie H, Castel V, Foot A, Ladenstein R . Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer. 2008; 99(7):1027-33. PMC: 2567095. DOI: 10.1038/sj.bjc.6604640. View

Allard M, Oger R, Vignard V, Percier J, Fregni G, Perier A . Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One. 2011; 6(6):e21118. PMC: 3119680. DOI: 10.1371/journal.pone.0021118. View

Elias S, Delestre C, Courel M, Anouar Y, Montero-Hadjadje M . Chromogranin A as a crucial factor in the sorting of peptide hormones to secretory granules. Cell Mol Neurobiol. 2010; 30(8):1189-95. PMC: 11498877. DOI: 10.1007/s10571-010-9595-8. View

Morandi F, Scaruffi P, Gallo F, Stigliani S, Moretti S, Bonassi S . Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins. PLoS One. 2012; 7(1):e29922. PMC: 3253802. DOI: 10.1371/journal.pone.0029922. View

Prigione I, Penco F, Martini A, Gattorno M, Pistoia V, Morandi F . HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2010; 50(5):966-72. DOI: 10.1093/rheumatology/keq418. View

Morandi F, Corrias M, Levreri I, Scaruffi P, Raffaghello L, Carlini B . Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunol Immunother. 2011; 60(10):1485-95. PMC: 3426043. DOI: 10.1007/s00262-011-1052-0. View

Gowda M, Godder K, Kmieciak M, Worschech A, Ascierto M, Wang E . Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med. 2011; 9:170. PMC: 3195752. DOI: 10.1186/1479-5876-9-170. View

De Bernardi B, Gerrard M, Boni L, Rubie H, Canete A, Di Cataldo A . Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol. 2009; 27(7):1034-40. DOI: 10.1200/JCO.2008.17.5877. View

10.

Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C . Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol. 2009; 27(7):1014-9. DOI: 10.1200/JCO.2007.14.5839. View

11.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

12.

Coupel S, Moreau A, Hamidou M, Horejsi V, Soulillou J, Charreau B . Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood. 2006; 109(7):2806-14. DOI: 10.1182/blood-2006-06-030213. View

13.

Singh S, Law C . Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2012; 6(3):313-34. DOI: 10.1586/egh.12.15. View

14.

Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S . Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007; 67(13):6433-41. DOI: 10.1158/0008-5472.CAN-06-4588. View

15.

Gregorio A, Corrias M, Castriconi R, Dondero A, Mosconi M, Gambini C . Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule. Histopathology. 2008; 53(1):73-80. PMC: 2658025. DOI: 10.1111/j.1365-2559.2008.03070.x. View

16.

Roth J, Vogl T, Sorg C, Sunderkotter C . Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol. 2003; 24(4):155-8. DOI: 10.1016/s1471-4906(03)00062-0. View

17.

Dong Y, Lieskovska J, Kedrin D, Porcelli S, Mandelboim O, Bushkin Y . Soluble nonclassical HLA generated by the metalloproteinase pathway. Hum Immunol. 2003; 64(8):802-10. DOI: 10.1016/s0198-8859(03)00093-4. View

18.

Lee N, Ishitani A, Geraghty D . HLA-F is a surface marker on activated lymphocytes. Eur J Immunol. 2010; 40(8):2308-18. PMC: 3867582. DOI: 10.1002/eji.201040348. View

19.

Hsiao R, Seeger R, Yu A, OConnor D . Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest. 1990; 85(5):1555-9. PMC: 296605. DOI: 10.1172/JCI114604. View

20.

Cangemi G, Reggiardo G, Barco S, Barbagallo L, Conte M, DAngelo P . Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets Ther. 2012; 5:417-23. PMC: 3514851. DOI: 10.2147/OTT.S36366. View